Cantargia patent granted in Australia

Cantargia AB (”Cantargia”) has obtained a granted patent in Australia concerning
IL1RAP as a target molecule for antibody based therapy and diagnostic methods of
leukemia.
Based on this grant, Cantargia´s method for treatment of leukemia has protection
within Europe, South Africa and Australia. The corresponding application is
currently under review by authorities in e.g. USA, Japan and China.

For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com